Inhaled glycopyrronium bromide: a guide to its use in moderate to severe chronic obstructive pulmonary disease


    loading  Checking for direct PDF access through Ovid

Abstract

Inhaled glycopyrronium bromide (Seebri® Breezhaler® capsules), a once-daily, long-acting muscarinic receptor antagonist, is indicated as a long-term maintenance bronchodilator for the symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD). In randomized, controlled trials, inhaled glycopyrronium bromide (at a delivered dose of 44 μg) once daily was associated with significantly better improvements in lung function, dyspnoea scores, health status, exacerbation rates and/or exercise endurance time than placebo in patients with moderate to severe COPD, and was generally well tolerated.

    loading  Loading Related Articles